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Abstract
Background
Functional (psychogenic) movement disorders (FMD) have features associated with volun-
tary movement (e.g. distractibility) but patients report movements to be out of their control.
One explanation for this phenomenon is that sense of agency for movement is impaired.
The phenomenon of reduction in the intensity of sensory experience when movement is
self-generated and a reduction in sensory evoked potentials (SEPs) amplitude at the onset
of self-paced movement (sensory attenuation) have been linked to sense of agency for
movement.
Methods
We compared amplitude of SEPs from median nerve stimulation at rest and at the onset of
a self-paced movement of the thumb in 17 patients with FMD and 17 healthy controls.
Results
Patients showed lack of attenuation of SEPs at the onset of movement compared to reduc-
tion in amplitude of SEPs in controls. FMD patients had significantly different ratios of move-
ment onset to rest SEPs than did healthy controls at each electrode: 0.79 in healthy controls
and 1.35 in patients at F3 (t = -4.22, p<0.001), 0.78 in healthy controls and 1.12 at patients
C3 (t = -3.15, p = 0.004) and 0.77 in healthy controls and 1.05 at patients P3 (t = -2.88, p =
0.007).
Conclusions
Patients with FMD have reduced sensory attenuation as measured by SEPs at onset of
self-paced movement. This finding can be plausibly linked to impairment of sense of agency
for movement in these patients.
PLOS ONE | DOI:10.1371/journal.pone.0129507 June 19, 2015 1 / 6
a11111
OPEN ACCESS
Citation: Macerollo A, Chen J-C, Pareés I,
Kassavetis P, Kilner JM, Edwards MJ (2015) Sensory
Attenuation Assessed by Sensory Evoked Potentials
in Functional Movement Disorders. PLoS ONE 10(6):
e0129507. doi:10.1371/journal.pone.0129507
Editor: Bogdan Draganski, Centre Hospitalier
Universitaire Vaudois Lausanne - CHUV, UNIL,
SWITZERLAND
Received: January 14, 2015
Accepted: May 8, 2015
Published: June 19, 2015
Copyright: © 2015 Macerollo et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: The authors have no support or funding to
report.
Competing Interests: M.J. Edwards received
funding for conference travel from Teva
pharmaceuticals and Orion. M.J. Edwards received
Royalties from Oxford University Press for book:
Oxford Specialist Handbook of Parkinson’s Disease
and Other Movement Disorders. There are no
patents, products in development or marketed
Introduction
Functional movement disorders (FMD) are part of the spectrum of functional neurological
symptoms, one of the most frequent diagnoses made in neurological practice [1]. FMD are
characterised by movements that require attention to manifest and conversely disappear with
distraction. These characteristics would be expected in movements that were voluntarily pro-
duced, but patients report movements to be out of their control. There is still a pervasive view
amongst neurologists that such patients are often feigning their symptoms, and this in part
may explain the lack of interest in managing such patients, despite the common and disabling
nature of functional symptoms.
A key issue therefore in understanding the nature and pathophysiology of FMD is the study
of sense of agency. This would be expected to be impaired given patients’ report of lack of con-
trol over what appear to be voluntary movements. Sensory attenuation (SA) describes a phe-
nomenon associated with normal movement where there is a different perception of identical
sensory inputs depending on whether they are self-generated or externally generated [2].Sti-
muli which are self-generated are associated with a reduction in the perceived intensity of the
stimulus; for example while one cannot tickle oneself, one can be tickled by others [3–8]. SA is
proposed to be a characteristic of voluntary movement, and importantly it has been proposed
as an implicit measure of the sense of agency for movement. Recently, we have demonstrated
abnormal SA in patients with FMD. We used a classic “force matching” paradigm where sub-
jects are asked to match a force delivered to their finger either by pressing down directly on
their finger or operating a robot to press down on their finger [9]. This requires a complex
experimental set-up and we were interested in developing a protocol that could probe the same
aspect of movement control but in a simpler way and thus could be more suitable as a potential
biomarker for FMD for future clinical studies. Here, we report the results of a study examining
suppression of sensory evoked potentials (SEPs) at the onset of self-generated movements in
healthy participants and FMD patients. We hypothesised that patients with FMD would have
less SEPs suppression at the onset of movement compared to healthy controls.
Material and Methods
Participants
Seventeen patients with FMD affecting body parts excluding upper limbs were recruited from
outpatient clinics at The National Hospital for Neurology and Neurosurgery, Queen Square,
London, UK. They had documented or clinically established FMD following Fahn andWil-
liams criteria [10]. Patients with sensory abnormalities were excluded. Seventeen healthy vol-
unteers matched with respect of gender, age and handedness were studied as the control group
(Table 1). The study was approved by the local institutional ethics committee. Written consent
was obtained from all participants according to the declaration of Helsinki.
Procedure and experimental design
Participants were seated in a comfortable armchair with hands relaxed on the armrest of the
chair and their eyes closed. SEPs were elicited by electrical stimulation of the right median
nerve at the wrist using a constant current square-wave pulse (0.2 ms duration). The anode
was placed over the median nerve at the wrist and the cathode 2 cm proximal to the anode.
The intensity used was the motor threshold for each subject. EEGs were recorded over the
scalp on the left with three Ag/AgCl scalp electrodes at three sites on according to the Interna-
tional 10–20 System (F3, C3, and P3). The reference electrode was placed on the right mastoid
and the ground on the left mastoid. Electrode impedance was monitored regularly during the
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course of the experiment and was kept less than 5kΩ. Surface EMG of right abductor pollicis
brevis (APB) was monitored simultaneously.
SEPs were recorded in two conditions presented in a randomised order in a single session.
In the rest condition, the subjects were relaxed and instructed not to react to the stimulus
which was delivered at a frequency of 2.1Hz. In the movement condition, they were instructed
to make a self-paced abduction movement of the right thumb. When the EMG signal recorded
from the APB rose above 0.15 microvolts the median nerve stimulus was triggered, thus
recording an SEPs at the onset of movement. For each condition, 500 traces were recorded.
Each trace lasted 470ms. During recording, the sampling rate was set at 2000Hz, and data were
online filtered with 20-3000Hz band-pass filter (CED1401 plus, Cambridge Electronics design,
Cambridge, UK), averaged and stored in a computer for off-line analysis. Trials with artefacts
exceeding 100μV were manually rejected. The order of the two sessions was counterbalanced
across subjects.
Data analysis
Wemade measurements on the following SEPs components: N30 at frontal electrode and N20
at central and parietal electrodes. For the identification of the amplitudes, we used the follow-
ing criteria. N30 was defined as the peak-to-peak values at frontal lead formed between 23–33
ms after the sensory stimulus was given. We measured N20 as the peak-to-peak values between
14 and 22ms after the onset of the sensory stimulation at central and parietal electrodes.
SPSS Statistics software (version 21.0.0) was used for the statistical analysis. Our measure of
SEPs suppression was the ratio between SEPs amplitude at the onset of movement and baseline
SEPs amplitude, and was analysed for the three EEG components. Normality of errors was
assessed using the Kolmogorov-Smirnoff test. When not normally distributed, the data were
subjected to a Log10 transformation. P-values for categorical variables were calculated with the
use of Fisher's exact test. We conducted a repeated measures multi-way analysis of variance
(ANOVA) with the following factors: SEPs COMPONENTS (F3, C3, P3) and GROUP
(patients vs. healthy controls).Post-hoc tests were conducted with Bonferroni corrections for
multiple comparisons. P values less than 0.05 were considered to be significant.
Table 1. Demographic and Clinical profile of the Participants.
Patients Healthy Control p-value
Age (years)
Mean (± Standard Deviation) 45.5 (±7.6) 48 (±7.4) 0.14
Sex (n)
Male 5 7 0.45
Female 12 10 0.45
Handness
Right 17 17 0.33
Main functional symptoms (n)
Fixed dystonia of limbs 5 NA
Functional gait impairment 7 NA
Fixed dystonia of neck 1 NA
Functional palatal tremor 1 NA
Functional weakness 3 NA
doi:10.1371/journal.pone.0129507.t001
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Results
Demographic characteristics of the participants are shown in Table 1. Clinical features
included an acute onset and rapid progression of the symptoms after a minor peripheral injury.
Most had an immediate dramatically positive response to Botulinum Toxin injections and, typ-
ically, they had a history of sudden and spontaneous remissions and relapses.
The amplitudes and latencies of evoked potentials in control and patient groups in the rest
condition were not different (Table 2).
We first analysed our measure of SA (ratio between SEPs amplitude at onset of movement
and at rest) in healthy controls and patients with FMD and explored whether there were differ-
ences. A repeated measures ANOVA with SEPs COMPONENTS (F3, C3 and P3) as within-
subjects factors and GROUP as between-subjects factor revealed that there was a significant
main effect of GROUP (F(1,21) = 0.88, p =< 0.001). Post Hoc exploration of this effect
revealed that this was due to an absence of SEPs suppression in patients (ratio> 1for all the
SEPs components) compared to healthy controls, who had SEPs suppression (ratio< 1 for all
the SEPs components) (“Fig 1”). A significant difference was found between the two groups for
the ratio SEPs movement onset/rest in each electrode: 0.79 in healthy controls and 1.35 in
patients at F3 (p< 0.001, t = -4.22), 0.78 in healthy controls and 1.12 at patients C3 (p = 0.004,
t = -3.15) and 0.77 in healthy controls and 1.05 at patients P3 (t = -2.88, p = 0.007). We found
Table 2. Amplitudes and latencies of representative SEPs peaks at rest in patients and controls.
controls patients t -value p-value
Amplitude (μV) N30 (F3) 2.31±0.96 [0.23] 1.97±1.23 [0.30] 0.91 >0.05
N20 (C3) 2.77±1.17 [0.28] 2.43±1.14 [0.28] 0.83 >0.05
N20 (P3) 2.76±1.24 [0.30] 2.48±1.22 [0.30] 0.67 >0.05
Latency (ms) N30 (F3) 28.64±1.73 [0.41] 28.76±0.83 [0.20] -0.25 >0.05
N20 (C3) 17.42±0.94 [0.22] 18.01±1.27 [0.31] -1.53 >0.05
N20 (P3) 17.88±0.93 [0.22] 18.17±1.01 [0.24] - 0.88 >0.05
Values are mean ± standard deviation [standard error of the mean].
doi:10.1371/journal.pone.0129507.t002
Fig 1. Ratio of SEPs amplitude at the onset of movement and at rest in patients and controls.
doi:10.1371/journal.pone.0129507.g001
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no significant effect of SEPs ELECTRODE (p = 0.34) nor a SEPs ELECTRODE x GROUP
(p = 0.11) interaction.
Discussion
In this study we have explored the physiological phenomenon of SEPs suppression at the onset
of movement in patients with FMD.We have found that patients with FMD did not display
attenuation of N20 and N30 amplitudes at the onset of movement compared to healthy controls.
Suppression of SEPs around the onset of a voluntary movement is a well described physiological
phenomenon [11], and is plausibly the electrophysiological correlate of the psychophysiological
reduction in intensity of self-generated sensory stimuli probed by previously described tasks
such as the force matching task [9]. Indeed, the attenuation of the intensity of sensations and
their electrophysiological/functional imaging correlates when they are self-generated is a widely
reported phenomenon across sensory domains [12,13]. The link between sense of agency and
SA has been made in various studies in healthy people and in clinical populations including
patients with schizophrenia and people with delusional beliefs [14]. The proposal is that SA
reflects a “labelling” of sensations (including those produced by movement) as self-generated,
and if this is reduced, then it is more likely that sensations will be inferred to be externally gener-
ated and lack a sense of agency for their production.
Movement abnormalities in patients with FMD have features that one would typically asso-
ciate with a strong sense of “voluntariness”, in particular the requirement for attention for the
abnormal movement to occur and the resolution of the abnormal movement with distraction
of attention. However, patients report the movements to be out of their control. This paradox
likely underlies much of the ambivalence about the “genuineness” of FMD. We have previously
used a force-matching task to compare SA in patients with FMD and healthy controls, and
found a reduction in SA in patients with FMD. Here we extend these findings by exploring an
electrophysiological correlate of movement which is plausibly linked to SA as measured by the
force-matching task. We therefore have converging evidence for a dysfunction in a specific
aspect of the physiology of motor control, and intriguingly one which has been linked to the
process of conferring sense of agency for movement.
In contrast to the force matching task, the paradigm used in the present study is technically
easy with only simple equipment required and a short experimental time. There is a need for
biomarkers of functional motor symptoms, for example for use in clinical trials of (novel) treat-
ments. If these results can be confirmed, and importantly if normalisation of this measure of
SA can be shown to occur with improvement of symptoms with treatment, then this could be a
suitable biomarker for future studies. We do not suggest that sensory attenuation (at least as
we have tested it here) is likely to be a useful diagnostic biomarker of FMD. We think it is likely
that there will be abnormalities of sensory attenuation in “organic” movement disorders,
though the mechanism of this abnormality will, we suggest, be fundamentally different from
the one we propose for FMD.
We acknowledge some limitations to our study. First, the sample size is small and we cannot
exclude that in a larger cohort data may have greater statistical efficiency. However, we chose
patients with clinically typical FMD using standardized criteria and believe that they do accu-
rately represent patients with this diagnosis. Furthermore, the fact that we were able to show a
significant group effect with a relatively small sample size suggests the effect sizes in question are
relatively large. Second, as in our previous study on force matching [9],we did not include
patients with functional tremor, the most common FMD, because tremor commonly involves
upper limbs and this was an exclusion criterion for the study. Third, we have speculated that sup-
pression of SEPs at the onset movement is the electrophysiological correlate of the phenomenon
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of SA assessed by a force-matching paradigm, but we did not directly compare the two phenom-
ena in this study, and therefore this remains a speculative interpretation. Fourth, as in our previ-
ous force matching study, we deliberately assessed clinically unaffected body parts. We therefore
cannot demonstrate via this study whether the phenomenon we observed is a trait of patients
with FMD (or related to other co-morbidities) or is genuinely related to the state of having a
functional movement disorder.
In conclusion, these results confirm a deficit in SA for self-paced movement in patients with
FMD, which could be plausibly linked to a disruption in sense of agency for movement. The
measurement of SA in this relatively simple paradigm is an interesting candidate biomarker for
FMD which could be explored in future work.
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